(redirected from Psoriasis Area and Severity Index)
PASIPsoriasis Area and Severity Index
PASIProvincial Approach to Student Information (Canadian education initiative)
PASIPublic Authority for Social Insurance
PASIPan American Studies Institute
PASIPreapplication Statement of Intent (FAA)
PASIProfessional Account Services Inc.
PASIProduction, Availability, Shipments, Inventory
PASIPioneer Air Systems, Inc.
PASIProfessional Associate, Chartered Surveyors' Institution (now Associate, Royal Institution of Chartered Surveyors; UK)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis.
The severity of psoriasis was assessed according to Psoriasis Area and Severity Index (PASI), and body surface area (BSA) measurement.
Additionally, more than half of patients treated with Enstilar achieved a 75% improvement in Psoriasis Area and Severity Index score from baseline.
At week 16, the Psoriasis Area and Severity Index (PASI) percent improvement from baseline was within the prespecified equivalence margin for ABP 501 compared to adalimumab.
Abbreviations: AE, adverse event; Cl, confidence interval; NAPSI, Nail Psoriasis Severity Index; mtNAPSl, modified target Nail Psoriasis Severity Index; PASI, psoriasis area and severity index; PGA, physician global assessment; SD, standard deviation; SGA, subject global assessment; shNAPSI, single hand Nail Psoriasis Severity Index.
The Psoriasis Area and Severity Index (PASI) (6) scores of the patients were calculated by the same dermatologist.
Between September 2010 and September 2011, we have been studying the changes of the PASI (Psoriasis Area and Severity Index) score in the case of our ward's patients suffering from psoriasis who underwent our complex dermatological treatment.
The drug had a significantly better benefit-risk profile as measured by the number of days patients spent with at least a 75% improvement from baseline in Psoriasis Area and Severity Index (PASI) scores while also remaining free of study drug-related adverse events, Dr.
Results of the 352-patient trial showed that 41% of patients treated with 30 milligrams of the drug, apremilast, twice a day, saw a 75% reduction in symptoms as measured by a score known as the Psoriasis Area and Severity Index (PASI-75) after 16 weeks.
The cohort had a mean Psoriasis Area and Severity Index score of about 24 and body surface involvement of about 30%.